Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Earlier de-escalation of DAPT to monotherapy, particularly ticagrelor, is an appropriate strategy supported by trial evidence for patients undergoing PCI.
inhibition, good control of ischaemic risk factors and a minimally thrombogenic stent design and deployment, it is rational that earlier de-escalation to monotherapy, particularly with ticagrelor, is often appropriate, reserving longer-duration DAPT for those with highest ischaemic risk but where bleeding risk is not high. A body of trial evidence now supports this. As well as earlier de-escalation of DAPT, future developments in PCI might include increased use of 'leave nothing behind' strategies and further pharmacological options for optimisation of ischaemic risk factors.
No takes yet. Share an insight, caveat, or question.
William A. Parker (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: